Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Ono Pharmaceutical Co: Clinical Trials & FDA Approval Profile

Ono Pharmaceutical Co (Global / Institutional) sponsors 26 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 18 active protocols (11 recruiting now), 8 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)149 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Ono Pharmaceutical Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)26
Active Pipeline (Recruiting Now)18 (11)
Completed vs Stopped Early8 / 0 (0.0%)
Median Closed Actual Enrollment149 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Ono Pharmaceutical Co
Hospital Research SiteLocationShared Protocols
National Cancer Center HospitalChuo-ku, Tokyo4
Mayo Clinic FloridaJacksonville, FL4
Osaka Metropolitan University HospitalOsaka4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Ono Pharmaceutical Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06948448A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab VersusPhase IIRECRUITING
NCT06579573ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.Phase IIIRECRUITING
NCT07429266INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)Phase IIIRECRUITING
NCT06936943ONO-4538 Study in Patients With Richter's TransformationPhase IIRECRUITING
NCT06590896Safety of Cenobamate in Japanese Subjects With Partial Onset SeizuresPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Ono Pharmaceutical Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI